MYDA Advisors’s Definium Therapeutics DFTX Stock Holding History

MYDA Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,000	Closed	-$104K	–	289
2021 Q2	$104K	Buy	+2,000	New	+$105K	0.03%	255

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return

MYDA Advisors's DFTX Position: Q3 2021 in Review

MYDA Advisors sold out of Definium Therapeutics (DFTX) in Q3 2021, closing a stake of 2,000 shares — an estimated $104K sold.

MYDA Advisors first reported a position in DFTX in Q2 2021 and held it in 1 quarter. The position peaked at $104K in Q2 2021. 174 funds tracked by Wall St. Rank hold DFTX as of Q3 2021.

MYDA Advisors reported no remaining Definium Therapeutics position as of Q3 2021 after selling out during the quarter.
MYDA Advisors sold 2,000 Definium Therapeutics shares in Q3 2021, an estimated $104K.
MYDA Advisors first reported a position in Definium Therapeutics in Q2 2021 and held it in 1 quarter.
MYDA Advisors's Definium Therapeutics position peaked at $104K in Q2 2021.
174 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2021.

Based on MYDA Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.